PsychPGx Lab Publications

Select Publications

  • Liu C, Maruf AA, Bousman CA. (2020). Reporting of clozapine-induced gastrointestinal hypomotility and factors associated with fatal outcomes in Canada: A pharmacovigilance database study. Psychiatry Research.
  • Jessel C, Mostafa S, Potiriadis M, Everall IP, Gunn JM, Bousman CA. (2020). Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients. Pharmacogenetics and Genomics
  • Maruf AA, Fan M, Arnold P, Mueller DJ, Aitchison K, Bousman CA. (2020). Pharmacogenetic testing options relevant to psychiatry in Canada. The Canadian Journal of Psychiatry.
  • Lacaze P, Ronaldson K, Zhang E, Alfirevic A, Shah H, Newman L, Strahl M, Smith M, Bousman CA, Francis B, Morris AP, Wilson T, Rossello F, Powell D, Vasic V, Sebra R, McNeil J, Pirmohamed M. (2020). Genetic associations with clozapine-induced myocarditis in patients with schizophrenia. Translational Psychiatry, 10, 37.
  • Hicks J, Bishop J, Gammal R, Sangkuhl K, Bousman CA, Leeder JS, Lerena A, Muller D, Ramsay L, Scott S, Skaar T, Caudle K, Klein T, Gaedigk A. (2019). A call for clear and consistent communications regarding the role of pharmacogenetics in antidepressant pharmacotherapy. Clinical Pharmacology & Therapeutics, 107(1): 50-52.
  • Lesche D, Mostafa S, Everall I, Pantelis C, Bousman CA. (2019). Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity. The Pharmacogenomics Journal.
  • Bousman CA, Zierhut H, Muller D. (2019). Navigating the labyrinth of pharmacogenetic testing: A guide to test selection. Clinical Pharmacology & Therapeutics.
  • Maruf AA, Greenslade A, Arnold A, Bousman CA. (2019). Antidepressant pharmacogenetics in children and young adults: A systematic review. Journal of Affective Disorders.
  • Bousman CA. (2019). CYP2D6 testing to guide risperidone and aripiprazole therapy. The Lancet Psychiatry.
  • Fan M and Bousman CA. (2019). Commercial Pharmacogenetic Tests in Psychiatry: Do they Facilitate the Implementation of Pharmacogenetic Dosing Guidelines? Pharmacopsychiatry
  • Bousman CA, Al Maruf A, Muller D. (2019). Towards the integration of pharmacogenetics in psychiatry: A minimum, evidence-based genetic testing panel. Current Opinion in Psychiatry.
  • Bousman CA, Arandjelovic K, Mancuso SG, Eyre H, Dunlop BW. (2018). Pharmacogenetic tests and depressive symptom remission: A meta-analysis of randomized controlled trials. Pharmacogenomics.
  • Bousman CA and Müller DM. (2018). Pharmacogenetics in Psychiatry: A companion, rather than competitor, to protocol-based care. JAMA Psychiatry , 75(10): 1090
  • Bousman CA, Eyre H, Allen J. (2018). Pharmacogenetic Tests in Psychiatry. American Journal of Psychiatry, 175(2): 189.
  • Bousman CA and Dunlop BW. (2018). Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetics-based decision support tools. The Pharmacogenomics Journal, 18(5): 613-622.
  • Chang D, Eyre H, Abbott R, Coudreaut M, Baune B, Shaman J, Lavretsky H, Lenze E, Merrill D, Singh A, Mulsant B, Reynold C, Muller D, Bousman, CA. (2018). Pharmacogenetic guidelines and decision support tools for depression treatment: Application to late-life. Pharmacogenomics, 19(16): 1269-1284.
  • Arandjelovic K, Eyre H, Lenze E, Singh AB, Berk M, Bousman CA. (2018). The role of depression pharmacogenetics decision support tools in shared decision making. Journal of Neural Transmission.
  • Bousman CA, Jaksa P, Pantelis C. (2017). Systematic evaluation of commercial pharmacogenetic testing in psychiatry: A focus on CYP2D6 and CYP2C19 allele coverage and results reporting. Pharmacogenetics and Genomics, 27(11):387-393.
  • Bousman CA, Forbes M, Jayaram M, Eyre H, Reynolds C, Berk M, Hopwood M, Ng C. (2017). Antidepressant prescribing in the precision medicine era: A prescriber's primer on pharmacogenetic tools. BMC Psychiatry 17(1): 60-67.
  • Bousman CA, Mueller D, Ng C, Byron K, Berk M, Singh A. (2017). Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: A 10-week open-label study. Pharmacogenetics and Genomics, 27(1) 1-6.
  • Bousman CA and Hopwood M. (2016). Commercial pharmacogenetic-based decision support tools in psychiatry. The Lancet Psychiatry
  • Bousman, C.A., Sarris, J., Won, ES., Chang, HS., Singh, A., Lee, HY., Ham, BJ., Tan, CH., Lee, MS., Ng, CH. (2014). Escitalopram efficacy in depression: A cross-ethnicity examination of the serotonin transporter promoter polymorphism. Journal of Clinical Psychopharmacology, 34(5): 645-8.

See more publications: PubMed and Scholar

All rights reserved to PsychGx Lab / Designed by